CFRX ContraFect Corporation

1.50
+0.20  (15%)
Previous Close 1.30
Open 1.40
Price To book 4.00
Market Cap 62.48M
Shares 41,656,000
Volume 109,555
Short Ratio 4.71
Av. Daily Volume 45,298

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced May 25, 2017 - data due 4Q 2018.
CF-301
Serious infections caused byStaph aureus including MRSA

Latest News

  1. CFRX: Phase 2 Study of CF-301 in Patients with Bacteremia Underway…
  2. ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
  3. CFRX: Final Logistics Being Completed For Initiation of Phase 2 Trial of CF-301 in mid-2017
  4. ContraFect reports 1Q loss
  5. ContraFect Announces First Quarter 2017 Financial Results
  6. ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
  7. ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
  8. CFRX: Phase 2 Trial of CF-301 to Initiate in mid-2017
  9. CORRECTION - ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  10. ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  11. ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
  12. Lisa Ricciardi to Join Board of Directors
  13. ContraFect Provides Program Update
  14. ContraFect to Present at Biotech Showcase 2017 Conference
  15. Is ContraFect Corp (CFRX) A Good Stock To Buy?
  16. ContraFect Corp. :CFRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  17. The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
  18. ContraFect to Present at 28th Annual Piper Jaffray Healthcare Conference
  19. ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301